Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) COO Sells 1,198 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) COO Julianne Bruno sold 1,198 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the sale, the chief operating officer now owns 8,263 shares of the company’s stock, valued at approximately $350,516.46. The trade was a 12.66 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CRISPR Therapeutics Stock Up 2.6 %

Shares of NASDAQ:CRSP opened at $43.49 on Thursday. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $76.86. The company has a 50-day moving average price of $43.02 and a 200 day moving average price of $45.65. The company has a market cap of $3.73 billion, a P/E ratio of -9.95 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Boston Family Office LLC lifted its stake in shares of CRISPR Therapeutics by 2.2% in the third quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock valued at $459,000 after purchasing an additional 213 shares during the period. Bedell Frazier Investment Counselling LLC increased its holdings in CRISPR Therapeutics by 0.8% in the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock valued at $1,238,000 after buying an additional 218 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of CRISPR Therapeutics by 1.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock valued at $586,000 after acquiring an additional 231 shares during the period. Intellectus Partners LLC boosted its stake in shares of CRISPR Therapeutics by 3.6% during the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock worth $281,000 after acquiring an additional 250 shares in the last quarter. Finally, Farrow Financial Inc. grew its holdings in shares of CRISPR Therapeutics by 1.4% in the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock worth $777,000 after acquiring an additional 270 shares during the period. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. JMP Securities reissued a “market outperform” rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Stifel Nicolaus cut their price target on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. Evercore ISI upgraded shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and upped their price objective for the company from $60.00 to $99.00 in a research note on Friday, February 14th. Bank of America cut their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, TD Cowen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price for the company in a research report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, CRISPR Therapeutics has an average rating of “Hold” and a consensus target price of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.